EASD 2026 28 September - 2 October 2026

UBT251, a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial

Authors :

Zhiguang Zhou¹; Dexue Liu²; Jiao Sun³; Sihong Wang⁴; Hongyan Shu⁵; Wenli Sun⁶; Haifang Wang⁷; Li Cong⁸; Li Mao⁹; Liujun Fu¹⁰; Shenglian Gan¹¹; Lili Zhang¹²; Huiru Yan¹³; Nicolas Belmar¹⁴; Haiyan Zhang¹³

Affiliations

View Details Hide Details

Keywords

Diabetes

Congress oral presentation

Pipeline

PHASE 2 (RCT)

Search Science Hub

Are you a healthcare professional?

UBT251, a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial

Search Science Hub

Are you a healthcare professional?

UBT251, a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial​

UBT251, a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial